IR Overview

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.


SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we have identified over 30 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs.

$4.270.00 (0.00%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume0
Today's Open$0.00
Previous Close$4.27
Data as of 03/23/17 4:00 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
03/22/17Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares (“ADSs”) at a price to the public of $4.20 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 ADSs at the public offer... 
Printer Friendly Version
03/21/17Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom, March 21, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to gran... 
Printer Friendly Version
03/15/17Adaptimmune Broadens Executive Team
PHILADELPHIA and OXFORD, United Kingdom, March 15, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has broadened its executive team with the appointment of co-founder, Helen Tayton-Martin, Ph.D., M.B.A, to the newly-created role of Chief Business Officer, and Mr. William (Bill) Bertrand, Jr., J.D., as Chief Operating Officer. Both appointments are effective immediately. Adaptimmune has an unrivalled por... 
Printer Friendly Version
03/13/17Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
– Opened two new INDs for wholly-owned SPEAR® T-cell therapies; Company now has four open INDs in 11 indications – – Received orphan designation, PRIME regulatory support and Breakthrough Therapy designation for NY-ESO SPEAR T-cell – – Received FDA notification of permission to proceed with new cell manufacturing process – – Conference call to be held today at 8:00 a.m. EDT (12:00 p.m. GMT) – PHILADELPHIA and OXFORD, United Kingdom, March 13, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeu... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.